An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
IMV to Present at IMMUNOLOGY™ 2022, the AAI Annual Meeting
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
IMV Inc. (NASDAQ: IMV) announced its participation at the IMMUNOLOGY™ 2022 meeting, held from May 6-10, 2022, in Portland, Oregon. The company will present a poster titled “Proteomic analysis of plasma exosomes as biomarkers of response to MVP-S based immunotherapy”, showcasing research by Dr. Brennan Dirk on May 7. IMV is advancing cancer therapies through its DPX® platform, with MVP-S in trials for various cancers, including DLBCL, ovarian, bladder, and breast cancers.
Positive
None.
Negative
None.
DARTMOUTH, Nova Scotia & CAMBRIDGE, Mass.--(BUSINESS WIRE)--
IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX® platform to treat solid and hematologic cancers, today announced the Company will present a poster at IMMUNOLOGY™ 2022, the annual meeting of the American Association of Immunologists (AAI). The meeting will be held May 6-10, 2022, in Portland, Oregon.
Presentation Details
Proteomic analysis of plasma exosomes as biomarkers of response to MVP-S based immunotherapy
Presenter: Brennan Dirk, Ph.D., Research Scientist, IMV Inc. Poster Number: 837 (abstract number)
Date/Time: Saturday, May 7 @ 2:30 – 3:45 PM
IMV Inc. is a clinical-stage immuno-oncology company advancing a portfolio of therapies based on the Company’s immune-educating platform: the DPX® technology. Through a differentiated mechanism of action, the DPX platform delivers instruction to the immune system to generate a specific, robust, and persistent immune response. IMV’s lead candidate, maveropepimut-S (MVP-S), delivers antigenic peptides from survivin, a well-recognized cancer antigen commonly overexpressed in advanced cancers. MVP-S also delivers an innate immunity activator and a universal CD4 T cell helper peptide. These elements foster maturation of antigen presenting cells as well as robust activation of CD8 T cell effector and memory function. MVP-S treatment has been well tolerated and has demonstrated defined clinical benefit in multiple cancer indications as well as the activation of a targeted and sustained, survivin-specific anti-tumor immune response. MVP-S is currently being evaluated in clinical trials for hematologic and solid cancers, including Diffuse Large B Cell Lymphoma (DLBCL) as well as ovarian, bladder and breast cancers. IMV is also developing a second immunotherapy leveraging the DPX immune delivery platform, DPX-SurMAGE. This dual-targeted immunotherapy combines antigenic peptides for both the survivin and MAGE-A9 cancer proteins to elicit immune responses to these two distinct cancer antigens simultaneously. A Phase 1 clinical trial in bladder cancer was initiated in early 2022. For more information, visit www.imv-inc.com and connect with us on Twitter and LinkedIn.
IMV Forward-Looking Statements
This press release contains forward-looking information under applicable securities law. All information that addresses activities or developments that we expect to occur in the future is forward-looking information. Forward-looking statements use such word as “will”, “may”, “potential”, “believe”, “expect”, “continue”, “anticipate” and other similar terminology. Forward-looking statements are based on the estimates and opinions of management on the date the statements are made. In the press release, such forward-looking statements include, but are not limited to, statements regarding the potential impact of the VITALIZE study and the anticipated date data from such study is available, the Company’s ability to advance its development strategy, as well as the prospects, for its lead immunotherapy and its other pipeline of immunotherapy candidates. However, they should not be regarded as a representation that any of the plans will be achieved. Actual results may differ materially from those set forth in this press release due to risks affecting the Company, including access to capital, the successful design and completion of clinical trials and the timely receipt of all regulatory approvals to commence, and then continue, clinical studies and trials and the receipt of all regulatory approvals to commercialize its products. IMV Inc. assumes no responsibility to update forward-looking statements in this press release except as required by law. These forward-looking statements involve known and unknown risks and uncertainties, and those risks and uncertainties include, but are not limited to, those related to the Company’s expected timeline associated with its cash runway; the Company’s priorities with MVP-S and its DPX delivery platform, the potential for its delivery platform and the anticipated timing of enrollment and results for its clinical trial programs and studies as others risks detailed from time to time in our ongoing quarterly filings and annual information form. Investors are cautioned not to rely on these forward-looking statements and are encouraged to read IMV’s continuous disclosure documents, including its current annual information form, as well as its audited annual consolidated financial statements which are available on SEDAR at www.sedar.com and on EDGAR at www.sec.gov/edgar
IMV Inc. is presenting a poster titled 'Proteomic analysis of plasma exosomes as biomarkers of response to MVP-S based immunotherapy'.
When is IMV's presentation at IMMUNOLOGY™ 2022?
IMV's presentation is scheduled for May 7, 2022, from 2:30 PM to 3:45 PM.
What is the focus of IMV's research presented in the poster?
The research focuses on identifying biomarkers of response to MVP-S based immunotherapy using proteomic analysis of plasma exosomes.
What is the significance of the DPX® platform for IMV Inc.?
The DPX® platform is crucial for IMV Inc. as it advances their immuno-oncology therapies, including MVP-S for various cancers.
What types of cancers is MVP-S being tested for?
MVP-S is currently being evaluated in clinical trials for hematologic and solid cancers, including Diffuse Large B Cell Lymphoma (DLBCL), ovarian, bladder, and breast cancers.
